MARKET

DVAX

DVAX

Dynavax Technolo
NASDAQ
10.89
-0.07
-0.64%
After Hours: 10.77 -0.12 -1.10% 19:26 12/05 EST
OPEN
10.95
PREV CLOSE
10.96
HIGH
11.03
LOW
10.87
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
14.63
52 WEEK LOW
9.20
MARKET CAP
1.28B
P/E (TTM)
-29.0477
1D
5D
1M
3M
1Y
5Y
1D
Republican Sen. Cassidy tells CDC not to adopt hepatitis b vaccine change
Seeking Alpha · 1d ago
CDC vaccine panel endorses change to newborn hepatitis b vaccine schedule
Seeking Alpha · 2d ago
CDC vaccine panel voting on hepatitis b shots postponed over confusion
Seeking Alpha · 2d ago
Assessing Dynavax After Recent Vaccine Progress and a 140% Five Year Share Price Surge
Simply Wall St · 2d ago
CDC vaccine panel set to debate hepatitis b shots, childhood immunizations
Seeking Alpha · 4d ago
Vaccine stocks slide as FDA official links COVID vaccines and heart conditions in young men
MarketWatch · 5d ago
Weekly Report: what happened at DVAX last week (1124-1128)?
Weekly Report · 6d ago
Dynavax Technologies (DVAX): Exploring Current Valuation After Recent Modest Share Price Rebound
Simply Wall St · 11/28 04:34
More
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Webull offers Dynavax Technologies Corp stock information, including NASDAQ: DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.